Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Receives $48.00 Consensus PT from Analysts

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $54.50.

Several equities analysts have commented on FTH shares. BTIG Research restated a “buy” rating and issued a $55.00 price target on shares of Sensei Biotherapeutics in a research note on Thursday. Leerink Partners initiated coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective on the stock. Citigroup initiated coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $55.00 price objective on the stock. Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st.

Sensei Biotherapeutics Stock Down 0.3%

NASDAQ FTH opened at $25.87 on Friday. Sensei Biotherapeutics has a one year low of $6.32 and a one year high of $37.90. The company has a market capitalization of $34.67 million, a PE ratio of -0.18 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. Equities research analysts anticipate that Sensei Biotherapeutics will post -16.61 earnings per share for the current year.

Insider Activity

In other news, CFO Brian C. Stephenson bought 9,391 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were purchased at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the purchase, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This represents a 53.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Anand Kiran Parikh bought 2,806 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of large investors have recently modified their holdings of FTH. Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth $22,758,000. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics during the first quarter worth $4,188,000. Bank of America Corp DE increased its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares during the last quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.